Incyte Corp
(NAS:INCY)
$
69.91
0.07 (0.1%)
Market Cap: 13.47 Bil
Enterprise Value: 11.73 Bil
PE Ratio: 499.36
PB Ratio: 4.25
GF Score: 89/100 Incyte Corp at Bank of America Merrill Lynch Health Care Conference Transcript
May 14, 2019 / 03:40PM GMT
Release Date Price:
$76.11
(+0.48%)
Ying Huang
BofA Merrill Lynch, Research Division - Director in Equity Research
Good morning, everyone. My name is Ying Huang. I'm the Head of Biotech Equity Research here at BofA Merrill Lynch. Welcome to the first day of our Global Healthcare Conference. So it's very nice to introduce our next presenting company, Incyte Pharmaceuticals. And we're pleased to have Christiana Stamoulis, the Chief Financial Officer of the company. Welcome to Vegas, I know it's the first time for you, and welcome to Incyte.
Christiana Stamoulis
Incyte Corporation - Executive VP & CFO
Thank you for having us.
Ying Huang
BofA Merrill Lynch, Research Division - Director in Equity Research
And then we also have Steven Stein. Dr. Stein is the Chief Medical Officer of Incyte and I think he has been with us for the last 3 years, probably in a row. And we also have Mike Booth, Head of Investor Relations at Incyte, with us.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot